Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson’s Patients Using Digital Mobility Outcomes
Wearable inertial sensors can be used to monitor mobility in real-world settings over extended periods. Although these technologies are widely used in human movement research, they have not yet been qualified by drug regulatory agencies for their use in regulatory drug trials. This is because the fi...
Main Authors: | Marco Viceconti, Sabina Hernandez Penna, Wilhelmus Dartee, Claudia Mazzà, Brian Caulfield, Clemens Becker, Walter Maetzler, Judith Garcia-Aymerich, Giorgio Davico, Lynn Rochester |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Sensors |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8220/20/20/5920 |
Similar Items
-
On the use of wearable sensors as mobility biomarkers in the marketing authorization of new drugs: A regulatory perspective
by: Marco Viceconti, et al.
Published: (2022-09-01) -
A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach
by: Lynn Rochester, et al.
Published: (2020-11-01) -
Cranio-Caudal Kinematic Turn Signature Assessed with Inertial Systems As a Marker of Mobility Deficits in Parkinson’s Disease
by: Karina Lebel, et al.
Published: (2018-01-01) -
Effect of Fear of Falling on Mobility Measured During Lab and Daily Activity Assessments in Parkinson’s Disease
by: Arash Atrsaei, et al.
Published: (2021-11-01) -
Regulatory Qualification of a Cross-Disease Digital Measure: Benefits and Challenges from the Perspective of IMI Consortium IDEA-FAST
by: David Nobbs, et al.
Published: (2023-09-01)